about
Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatmentTelomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications.Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virusShort-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.Epstein-Barr virus and telomerase: from cell immortalization to therapy.hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.Arachidonic acid-induced IL-6 expression is mediated by PKC alpha activation in osteoblastic cells.Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma.Immune senescence and cancer in elderly patients: results from an exploratory study.Different apoprotein(a) isoform proportions in serum and carotid plaque.Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.A comparative study of serum and synovial fluid lipoprotein levels in patients with various arthritides[Clinical value of antibodies to lysobisphosphatidic acid in patients with primary antiphospholipid syndrome]Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed GlioblastomaPredictive and prognostic significance of telomerase levels/telomere length in tissues and peripheral blood in head and neck squamous cell carcinomaTERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma PatientsImmune senescence and immune activation in elderly colorectal cancer patientsTERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma
P50
Q26798038-C0C5571A-4E69-490D-AFB6-1D3F2AD15EEEQ30248577-F961CC18-CC3F-4EC3-833E-C6F2C953B95FQ33216778-5B989892-71BD-4AF9-A574-D88B90C5D1ABQ35643026-8B01F31B-3385-49F6-A978-1CAA8755BC3AQ36346985-CCDFCA74-76BD-44CC-BFE7-8A7E6F4EE3A9Q37603448-D2E73FF2-819E-44C1-8AB8-07BB4275BC19Q37619108-844A63F2-BC12-4772-BB2E-A05507620398Q39187962-3E7D06E9-2A61-48F6-94D4-FABDA4A3F4CAQ40655682-F988530F-AB4A-4276-8657-F227D254175DQ40893503-60099068-ABEC-4C62-ACA5-FCFA33BCE69CQ42154956-0778F277-EE54-495B-AC9D-B615D0E08EDDQ48414742-FCB37122-AC46-4075-88DE-B1370BE7B84BQ51795856-BDA685EB-28FB-43E7-BD7A-DC094B08ED4FQ52719942-AA3EBCB5-CD92-494E-81AA-6F7373463F91Q61649491-84FE6C22-B4E8-4D64-B566-C16D3ECDD1F5Q84592754-868039C7-B357-4265-BB15-814664910FC4Q90258590-728C46DB-66AE-4DB1-BFA3-07B3CA087943Q91473851-107BB0CE-1012-4421-B7CD-CAD6796E9B6BQ91923588-BDCC790F-837B-4891-9DEF-533660EEC57BQ92722005-98560966-66C8-4B44-B51B-B6C25B313BF2Q92786505-BD35B724-41F9-4D5D-BFE5-DB94AE486681
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvia Giunco
@ast
Silvia Giunco
@en
Silvia Giunco
@es
Silvia Giunco
@nl
type
label
Silvia Giunco
@ast
Silvia Giunco
@en
Silvia Giunco
@es
Silvia Giunco
@nl
prefLabel
Silvia Giunco
@ast
Silvia Giunco
@en
Silvia Giunco
@es
Silvia Giunco
@nl
P108
P106
P1153
8604826300
P21
P31
P496
0000-0003-3760-1478